Results 181 to 190 of about 64,777 (300)

Epilepsy surgery: From bench to the clinics

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Recent advances in epilepsy surgery in patients with intractable epilepsy make it possible to study the mechanism of epilepsy in human brains. However, the true extent and propagation of each epileptogenic area from the epileptogenic focus in each patient is still difficult to perform “epilepsy cure” by surgery.
Tatsuya Tanaka
wiley   +1 more source

Does having bad epilepsy make you a good surgical candidate? A number needed to treat analysis

open access: yesEpilepsia Open, EarlyView.
Abstract Epilepsy surgery is an established treatment for drug‐resistant epilepsy, offering a realistic prospect of seizure freedom in well‐selected candidates. However, surgery is sometimes offered to individuals with a low probability of seizure freedom when it is framed as potentially “life‐saving” on the basis of the elevated mortality associated ...
Sallie Baxendale   +2 more
wiley   +1 more source

Crossed cerebellar diaschisis in status epilepticus: A systematic review of the literature. [PDF]

open access: yesEpileptic Disord
Tabaee Damavandi P   +6 more
europepmc   +1 more source

Neonatal seizures and GABAergic drugs: Scylla and Charybdis?

open access: yesEpilepsia Open, EarlyView.
Abstract Neonates have a high incidence of seizures that are frequently difficult to control with conventional first‐line anti‐seizure medications, which are gamma‐aminobutyric acid (GABA) agonists. The reasons for this clinical problem are multifold but are likely related to the unique physiology of the immature nervous system. Specifically, the early
Kerry W. Thompson   +2 more
wiley   +1 more source

Real‐world effectiveness of highly purified cannabidiol in epilepsy associated with 15q11.2‐q13.1 duplication and deletion syndromes: A multicenter study

open access: yesEpilepsia Open, EarlyView.
Abstract This multicenter retrospective study evaluated the effectiveness and safety of highly purified cannabidiol (CBD) in 22 patients with 15q11.2‐q13.1 duplication or deletion syndromes (15q‐DDS), including 12 with 15q duplication syndrome (dup15q) and 10 with Angelman syndrome (AS). Median (interquartile range [IQR]) age at CBD initiation was 14.5
Emanuele Cerulli Irelli   +14 more
wiley   +1 more source

Practical consensus recommendations for polytherapy involving stiripentol in Dravet syndrome: A nominal group approach

open access: yesEpilepsia Open, EarlyView.
Abstract Objectives Dravet syndrome (DS) is a drug‐resistant developmental and epileptic encephalopathy, often requiring three or more antiseizure medications (ASMs). Consequently, the therapeutic landscape is highly complex, combining DS‐specific agents (stiripentol, STP; cannabidiol, CBD; fenfluramine, FFA), non‐specific ASMs, and non‐pharmacologic ...
J. Helen Cross   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy